But Melanotan II has been linked to some serious side effects including kidney failure, nausea, skin flushing, skin cancer, and potential cardiovascular issues
New Oral GLP-1 Orforglipron Receives FDA Approval FDA-approved orforglipron is the first oral non-peptide GLP-1, offering weight loss and glycemic control without injections
Even though the impact of the microbiota-gut-brain axis in ASD has been frequently discussed, people have paid a great interest in nutritional interventions [13]
New findings from the landmark SELECT trial reveal that semaglutides cardiovascular benefits are only partly explained by reductions in waist size, suggesting broader protective effects beyond fat loss
Using GLP-1 medications
Some medications, such as antidepressants, steroids, or medications for diabetes, can interfere with weight loss